Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677716 · ClinicalTrials.gov registry record · Phase 2
Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse
A Phase 2 study of Glioblastoma Multiforme, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 7
- Study locations
NCT00677716 is a Phase 2 study of Glioblastoma Multiforme that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 41 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (57% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT00677716, a Phase 2 study of Glioblastoma Multiforme, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 7
- Study locations
Study Summary
Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out". This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.
Conditions Studied
Interventions
- DRUG 131I-chTNT-1/B MAb (Cotara)
Study Locations (7)
Other
- Manipal Institute for Neurological Disorders, - Bangalore
- Department of Neurosurgery Jaslok Hospital and Research Centre - Mumbai
- All India Instutite of Medical Sciences - New Delhi
Arizona
- Barrow Neurological Institute - Phoenix
Pennsylvania
- University of Pennsylvania, Department of Neurosurgery - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Kerala
- Amrita Institute of Medical Sciences and Research Center, - Kochi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677716
The ClinicalTrials.gov registry entry for NCT00677716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (57% lower). The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which 131I-chTNT-1/B MAb (Cotara) is the first listed.
NCT00677716 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, Arizona, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00677716 about?
NCT00677716 is a clinical study titled "Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse". Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus l...
What is the current status of trial NCT00677716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-07. Estimated completion is 2011-11.
What conditions does trial NCT00677716 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT00677716?
The interventions under investigation include: 131I-chTNT-1/B MAb (Cotara) (DRUG).
Who is sponsoring clinical trial NCT00677716?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00677716 being conducted?
This trial has 7 study locations across Arizona, Pennsylvania, South Carolina, Kerala. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.